Claims for Patent: 9,968,676
✉ Email this page to a colleague
Summary for Patent: 9,968,676
Title: | Subcutaneous anti-HER2 antibody formulations and uses thereof |
Abstract: | The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN.TM.), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. .alpha.,.alpha.-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided. |
Inventor(s): | Adler; Michael (Riehen, CH), Grauschopf; Ulla (Riehen, CH), Mahler; Hanns-Christian (Basel, CH), Stauch; Oliver Boris (Freiburg, DE) |
Assignee: | Genentech, Inc. (South San Francisco, CA) |
Application Number: | 15/053,217 |
Patent Claims: | 1. A highly concentrated, stable liquid pharmaceutical composition of pharmaceutically active anti-HER2 antibody for subcutaneous injection comprising: a. 100 to 150 mg/ml
anti-HER2 antibody, wherein the anti-HER2 antibody is a combination of Trastuzumab and Pertuzumab; b. 1 to 50.+-.5% mM of a buffering agent providing a pH of 5.5.+-.2.0; c. 150 to 250.+-.5% mM of a mixture of trehalose and sucrose as a first stabilizer
and 5 to 15 mM methionine as a secondary stabilizer; d. 0.01 to 0.08.+-.5% (w/v) of a nonionic surfactant; and e. 1,000 to 16,000 U/ml of at least one hyaluronidase enzyme.
2. The pharmaceutical composition of claim 1 comprising 120 mg/ml of the combination of Trastuzumab and Pertuzumab. 3. The pharmaceutical composition of claim 1, comprising 1'500 U/ml to 12,000 U/ml of the hyaluronidase enzyme. 4. The pharmaceutical composition of claim 3, comprising 2,000 U/ml of the hyaluronidase enzyme. 5. The pharmaceutical composition of claim 4, wherein the hyaluronidase enzyme is recombinant human hyaluronidase, rHuPH20. 6. The pharmaceutical composition of claim 1, wherein the buffering agent is a histidine buffer. 7. The pharmaceutical composition of claim 5, wherein the histidine buffer is a histidine chloride buffer at a pH of 5.5.+-.0.6. 8. The pharmaceutical composition of claim 6, wherein the histidine chloride buffer has a pH of 5.5. 9. The pharmaceutical composition of claim 1, wherein the nonionic surfactant is a polysorbate selected from the group consisting of polysorbate 20, polysorbate 80, and polyethylene-polypropylene copolymer. 10. The pharmaceutical composition of claim 9, wherein the nonionic surfactant is polysorbate 20. 11. An injection device comprising the highly concentrated stable ready for use pharmaceutical composition of claim 1. 12. A method of treating a disease or disorder which is amenable to treatment with an anti-HER2 antibody in a subject comprising administering to said subject a pharmaceutical composition according to claim 1 in an amount effective to treat said disease or disorder. 13. The method of claim 12, wherein the disease is cancer. 14. The method of claim 13, wherein the cancer is breast cancer. 15. The method of claim 14, wherein the cancer is HER2 overexpressing breast cancer. 16. A kit comprising a vial containing the highly concentrated stable ready for use pharmaceutical composition of claim 1 and instructions for subcutaneous administration of the composition to a patient. 17. The kit of claim 16 further comprising an injection device for subcutaneous administration of the pharmaceutical composition to the patient. |
Details for Patent 9,968,676
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bausch & Lomb Incorporated | VITRASE | hyaluronidase | Injection | 021640 | 05/05/2004 | ⤷ Try a Trial | 2029-07-31 |
Bausch & Lomb Incorporated | VITRASE | hyaluronidase | Injection | 021640 | 12/02/2004 | ⤷ Try a Trial | 2029-07-31 |
Amphastar Pharmaceuticals, Inc. | AMPHADASE | hyaluronidase | Injection | 021665 | 10/26/2004 | ⤷ Try a Trial | 2029-07-31 |
Akorn, Inc. | HYDASE | hyaluronidase | Injection | 021716 | 10/25/2005 | ⤷ Try a Trial | 2029-07-31 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2029-07-31 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2029-07-31 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.